KR20130037659A - 혈액응고인자 Ⅶ 및 Ⅶａ 유도체, 그들을 포함하는 결합체 및 복합체와 그들의 용도 - Google Patents

혈액응고인자 Ⅶ 및 Ⅶａ 유도체, 그들을 포함하는 결합체 및 복합체와 그들의 용도 Download PDF

Info

Publication number
KR20130037659A
KR20130037659A KR1020120111537A KR20120111537A KR20130037659A KR 20130037659 A KR20130037659 A KR 20130037659A KR 1020120111537 A KR1020120111537 A KR 1020120111537A KR 20120111537 A KR20120111537 A KR 20120111537A KR 20130037659 A KR20130037659 A KR 20130037659A
Authority
KR
South Korea
Prior art keywords
fac
gly
derivative
leu
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020120111537A
Other languages
English (en)
Korean (ko)
Inventor
김대진
이병선
홍성환
허용호
정성엽
권세창
Original Assignee
한미사이언스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미사이언스 주식회사 filed Critical 한미사이언스 주식회사
Publication of KR20130037659A publication Critical patent/KR20130037659A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020120111537A 2011-10-06 2012-10-08 혈액응고인자 Ⅶ 및 Ⅶａ 유도체, 그들을 포함하는 결합체 및 복합체와 그들의 용도 Abandoned KR20130037659A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110102099 2011-10-06
KR1020110102099 2011-10-06

Publications (1)

Publication Number Publication Date
KR20130037659A true KR20130037659A (ko) 2013-04-16

Family

ID=48044320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120111537A Abandoned KR20130037659A (ko) 2011-10-06 2012-10-08 혈액응고인자 Ⅶ 및 Ⅶａ 유도체, 그들을 포함하는 결합체 및 복합체와 그들의 용도

Country Status (18)

Country Link
US (1) US9597378B2 (enExample)
EP (2) EP2763693A4 (enExample)
JP (1) JP6108630B2 (enExample)
KR (1) KR20130037659A (enExample)
CN (1) CN103974716B (enExample)
AR (1) AR088267A1 (enExample)
AU (1) AU2012319308B2 (enExample)
BR (1) BR112014008224A2 (enExample)
CA (1) CA2851223A1 (enExample)
IL (1) IL231930A0 (enExample)
MX (1) MX354493B (enExample)
MY (1) MY168754A (enExample)
PH (1) PH12014500735A1 (enExample)
RU (1) RU2620072C2 (enExample)
SG (1) SG11201401205UA (enExample)
TW (1) TWI565715B (enExample)
WO (1) WO2013051900A2 (enExample)
ZA (1) ZA201402745B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015030479A1 (ko) * 2013-08-30 2015-03-05 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법
EP3348274A1 (en) 2013-01-31 2018-07-18 Hanmi Pharm. Co., Ltd. A method of virus inactivation in composition comprising factor vii

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN103599527A (zh) * 2013-08-16 2014-02-26 安源生物科技(上海)有限公司 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
DK3127923T3 (da) * 2014-03-31 2021-11-22 Hanmi Pharm Ind Co Ltd Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding
EP3373926B1 (en) 2015-11-10 2020-06-10 Sun Chemical Corporation Alkoxylated dispersing agents
KR102041671B1 (ko) * 2017-05-08 2019-11-28 가톨릭대학교 산학협력단 β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
WO2019240881A2 (en) * 2018-04-23 2019-12-19 Emory University Vip and vip agonists, nanoparticles, and uses in inflammatory t-cell mediated disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
AU2003242507A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2007509843A (ja) 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ＶＩＩ／ＶＩＩａ因子活性を有するハイブリッド分子
BRPI0406606A (pt) 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
ES2434032T3 (es) * 2005-06-17 2013-12-13 Novo Nordisk Health Care Ag Compuestos de FVIIA diméricos y multiméricos
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
KR100880509B1 (ko) 2006-10-16 2009-01-28 한미약품 주식회사 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
KR101104684B1 (ko) 2008-12-02 2012-01-16 이화여자대학교 산학협력단 관찰 방향 및 조명을 고려한 피부 질감 렌더링 방법 및 그 장치
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3348274A1 (en) 2013-01-31 2018-07-18 Hanmi Pharm. Co., Ltd. A method of virus inactivation in composition comprising factor vii
WO2015030479A1 (ko) * 2013-08-30 2015-03-05 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법

Also Published As

Publication number Publication date
MX354493B (es) 2018-03-08
BR112014008224A2 (pt) 2017-04-11
SG11201401205UA (en) 2014-05-29
WO2013051900A2 (en) 2013-04-11
TWI565715B (zh) 2017-01-11
PH12014500735A1 (en) 2022-05-11
MY168754A (en) 2018-11-30
AU2012319308B2 (en) 2017-08-31
AR088267A1 (es) 2014-05-21
EP3417881A1 (en) 2018-12-26
MX2014004099A (es) 2014-05-21
AU2012319308A1 (en) 2014-05-01
EP2763693A2 (en) 2014-08-13
ZA201402745B (en) 2016-04-27
JP2014530018A (ja) 2014-11-17
CA2851223A1 (en) 2013-04-11
NZ623726A (en) 2016-06-24
US20140271607A1 (en) 2014-09-18
IL231930A0 (en) 2014-05-28
RU2014115291A (ru) 2015-11-20
RU2620072C2 (ru) 2017-05-22
CN103974716A (zh) 2014-08-06
JP6108630B2 (ja) 2017-04-05
EP2763693A4 (en) 2015-12-09
US9597378B2 (en) 2017-03-21
TW201331223A (zh) 2013-08-01
CN103974716B (zh) 2016-08-24
WO2013051900A3 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
KR20130037659A (ko) 혈액응고인자 Ⅶ 및 Ⅶａ 유도체, 그들을 포함하는 결합체 및 복합체와 그들의 용도
KR101439817B1 (ko) 연장된 반감기를 갖는 변형된 응고 인자 ＶＩＩａ
HK1207591A1 (en) Chimeric clotting factors
JP6676551B2 (ja) 改変フォンウィルブランド因子
CA2649199C (en) Method of increasing the in vivo recovery of therapeutic polypeptides
JP2019507587A (ja) 変異切断型フォンウィルブランド因子
JP2019504621A (ja) 突然変異フォン・ヴィレブランド因子
TWI443106B (zh) 使用免疫球蛋白片段之ＶＩＩａ因子錯合物
HK1196565B (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
HK1196565A (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
NZ623726B2 (en) Blood coagulation factor ? and ?a derivatives, conjugates and complexes comprising the same, and use thereof
AU2012258466A1 (en) Modified coagulation Factor VIIa with extended half-life
HK1129421B (en) Modified coagulation factor vila with extended half-life

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20121008

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170830

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20121008

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180824

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180824

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190129

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181024

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190325

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190304

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190129

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20181024

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PC1904 Unpaid initial registration fee